Clinical Trials in Turkey / NCT03983512
Active, not recruiting
Not applicable
PULSTA Transcatheter Pulmonary Valve Pre-Approval Study
NCT03983512 · tracked via the Priya Life Science Turkey tracker
Condition(s) studied
Heart DiseasesPulmonary Valve RegurgitationPulmonary Valve StenosisTetralogy of Fallot
Investigational drug(s) / intervention(s)
PULSTA TPV System
PULSTA TPV System: PULSTA transcatheter pulmonary valve replacement.
Study summary
The purpose of the study is to evaluate the safety and effectiveness of the PULSTA Transcatheter Pulmonary Valve (TPV) System for the treatment of congenital or acquired pulmonary valve stenosis and/or regurgitation who require pulmonary valve replacement.
Eligibility
Inclusion Criteria:
* Body weight greater than or equal to 30 kilograms
* Pulmonary regurgitation moderate or severe pulmonary regurgitation or pulmonary valve stenosis with mean gradient \>35mmHg by echocardiography
* Main pulmonary artery trunk of ≥16 mm and ≤30 mm
* Patients willing to provide written informed consent and comply with follow-up evaluations.
Exclusion Criteria:
* Females of child-bearing potential who are unable to take adequate contraceptive precautions, are known to be pregnant, or are currently breastfeeding an infant up until 6 months after TPV implantation
* Pre-existing mechanical valve in pulmonary position or require concomitant repair of other cardiac valves
* Obstruction of the central veins to be approached for the TPV implantation
* Coronary artery compression confirmed by angiography
* A known severe allergy to Nickel
* A known hypersensitivity to any anticoagulation therapy, contrast agent or a hemorrhagic disease
* Suspected active infectious disease (e.g. endocarditis, meningitis)
* Life expectancy of less than 6 months
Primary outcome measure(s)
- Procedural/Device related serious adverse events at 6 months — 6 months
- Hemodynamic functional improvement at 6 months — 6 months
Hemodynamic functional improvement is a composite of mean RVOT gradient ≤30 mmHg by continuous wave Doppler and a pulmonary regurgitant fraction \<20% by cardiac magnetic resonance (MR)
Trial sites (11)
| Facility | City | Region | Status |
|---|---|---|---|
| Deutsches Herzzentrum Munchen | München | München | |
| Policlinico San Donato | Milan | San Donato Milanese | |
| Utrecht University Wilhelmina | Utrecht | Utrecht | |
| Erasmus Medical Center | Rotterdam | Wytemaweg | |
| Seoul National University Hospital | Seoul | Daehak-ro Jongno-gu | |
| Sejong General Hospital | Bucheon-si | Hohyun-ro, Sosa-gu | |
| Severance Hospital | Seoul | Yonsei-ro, Seodaemun-gu | |
| Gregorio Marañon hospital | Madrid | Madrid | |
| University Hospital La Paz | Madrid | Madrid | |
| Koc University Hospital | Istanbul | Topkapı, Zetinburnu/İstanbul | |
| Siyami Ersek Hospital | Istanbul | Üsküdar/İstanbul |
More Taewoong Medical Co., Ltd. trials in Turkey
PULSTA TPV Observational Study
Starting soon
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03983512 on ClinicalTrials.gov ↗ ← All trials in Turkey